Understand the source comparison
Pressure-lowering glaucoma drops vs neuroprotective peptides
Prostaglandin analogs mechanism: Latanoprost, bimatoprost increase uveoscleral outflow lowering intraocular pressure. Reduces mechanical stress on optic nerve. Cornerstone glaucoma treatment preventing progression in most patients. Topical once-daily administr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Prostaglandin analogs mechanism: Latanoprost, bimatoprost increase uveoscleral outflow lowering intraocular pressure. Reduces mechanical stress on optic nerve. Cornerstone glaucoma treatment preventing progression in most patients. Topical once-daily administration.
- Cerebrolysin neuroprotection: Supports ganglion cell survival through neurotrophic pathways. Doesn't lower pressure but protects neurons from pressure-related damage. Complementary mechanism addressing both cause (pressure) and consequence (neural damage). IV infusion required, more complex administration than drops. Research suggests combination superior to pressure lowering alone though not standard care currently.
- Beta-blocker and alpha agonist mechanisms: Timolol reduces aqueous humor production. Brimonidine reduces production and increases outflow plus possible neuroprotective effects. Work through completely different pathways than peptides. All glaucoma medications affect pressure or flow, peptides uniquely targeting neuronal survival.
- SeekPeptides helps understand combination protocols integrating peptides with conventional medications.